Gelonghui November 22 | Changshan Pharmaceutical surged 8%, while Shuanglu Pharmaceutical, Hanyu Pharmaceutical, Zhongsheng Pharmaceutical, and Dezhan Health rose. According to the news, on Tuesday (November 21) local time, the European Medicines Agency (EMA) stated in a letter published on its website that it and Novo Nordisk expect that the shortage of Ozempic (GLP-1 drug semeglutide) and Victoza liraglutide will worsen in the fourth quarter of 2023, and there will still be a shortage of Ozempic supply in the EU market in 2024.
减肥药板块反弹 常山药业涨超8%
The diet drug sector rebounded, and Changshan Pharmaceutical rose more than 8%
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.